Effect of methylglyoxal bis(guanylhydrazone) on hepatic, heart and skeletal muscle mitochrondrial carnitine palmitoyltransferase and β-oxidation of fatty acids

Methylglyoxal bis(guanylhydrazone) (MGBG) is an antileukemic agent and polyamine analog which inhibits S-adenosyl methionine decarboxylase. However, MGBG also produces mitochondrial structural damage and inhibition of β-oxidation. The present experiments were designed to determine if MGBG acts via carnitine palmitoyltransferase-A (CPT-A) inhibition. Liver, heart and skeletal muscle mitochondria were isolated from rats following a 24 h fast. MGBG was competitive with 1-carnitine. The MGBG CPT-A Ki were (mM): liver, 5.0 +/- 0.6 (n = 15); heart, 3.2 +/- 1.2 (n = 3); skeletal muscle, 2.8 +/- 1.0 (n = 3). Lysis of hepatic mitochondria with Triton X-100 yielded a Ki of 4.0 +/- 2.0. Purified hepatic CPT was also sensitive to MGBG inhibition (Ki = 4.5 mM). Spermine and spermidine, which are structurally similar to MGBG, did not inhibit CPT or acid-soluble product formation from 1-[14C]-palmitoyl-CoA. MGBG inhibited mitochondrial state 3 oxidation rates of palmitoyl-CoA and palmitoylcarnitine, as well as of glutamate. However, the fatty acid substrates were considerably more sensitive than glutamate to MGBG inhibition. MGBG also increased hepatic mitochondrial aggregation which was reversed by 1-carnitine. Fluorescence polarization, using diphenylhexatriene as a probe, indicated that MGBG increased membrane rigidity in a dose dependent manner. This effect was not reversed by 1-carnitine. The authors conclude that MGBG exhibits competitive competition with 1-carnitine for CPT. However, MGBG also exhibits a number of effects which may be mediated through membrane interaction and which are not necessarily reversed by carnitine